Prostate cancer 1: Diagnosis and active surveillance

  • Location:
    Warsaw Halls
  • Chairs:
     M. Brausi, Modena (IT)
     B. Djavan, Vienna (AT)
     P. Carroll, San Francisco (US)
     J.E. Hugosson, Göteborg (SE)
Can MRI identify prostate cancer in men with PSA less than 3 ng/ml?
 J.E. Hugosson, Göteborg (SE)
How and in which patients to perform a TRUS-MRI fusion biopsy? (Video)
 T.H. Kuru, Köln (DE)
Discussion
Active surveillance: Do we know the long term risk?
 R. Arnsrud Godtman, Gothenburg (SE)
Are there any new reliable triggers in active surveillance?
 P. Carroll, San Francisco (US)
The use of MRI in the follow-up of patients on AS: results of a prospective study
 M. Colombel, Lyon (FR)
Case presentation and discussion
 J. Barentsz, Nijmegen (NL)
DEBATE: Treatment of intermediate risk patients
What is the intermediate risk in 2015?
 S. Joniau, Leuven (BE)
Discussion
Focal therapy: A critical review
 W. Artibani, Verona (IT)
Extended lymphadenectomy: A critical review
 P. Carroll, San Francisco (US)
Discussion
ESUR Lecture: Which biomarkers are ready to use in clinical practice?
 Z. Culig, Innsbruck (AT)
Discussion
Robotic surgery for cT3 prostate cancer (Video)
 B. Rocco, Milan (IT)
Evolving role of open radical prostatectomy in high risk prostate cancer in the robotic era (Video)
 B. Djavan, Vienna (AT)
Discussion